<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor VIII, human plasma-derived: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor VIII, human plasma-derived: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor VIII, human plasma-derived: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8825" href="/d/html/8825.html" rel="external">see "Factor VIII, human plasma-derived: Drug information"</a> and <a class="drug drug_patient" data-topicid="11467" href="/d/html/11467.html" rel="external">see "Factor VIII, human plasma-derived: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135729"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Hemofil M;</li>
<li>Koate;</li>
<li>Koate-DVI</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051120"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F135740"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41bca916-fbad-4b58-b634-e51fe53bc8d4">Hemophilia A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A: </b>Individualize dosage based on clinical response and factor VIII activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2% of normal. Patients with inhibitory antibodies to factor VIII may require higher doses, more frequent administration, and/or selection of alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control and prevention of bleeding episodes or perioperative management: Note: </b>Dosage is expressed in units of factor VIII activity and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, individualized incremental recovery using factor VIII activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents (ages vary by product; see product-specific labeling for approved ages): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Formula for units required to raise blood level:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Number of Factor VIII Units required = body weight (in kg) x 0.5 units/kg per units/dL x desired factor VIII level increase (units/dL or %)</p>
<p style="text-indent:-2em;margin-left:10em;">For example, for a desired 100% level in a 25 kg patient who has an actual level of 20%: Number of Factor VIII Units needed = 25 kg x 0.5 units/kg per units/dL x 80% = 1,000 units</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment recommendations</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>): <b>Note:</b> Factor VIII level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent IV: Infants, Children and Adolescents: The following recommendations reflect guideline recommendations for general dosing requirements; may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels (if available) before the next dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor VIII Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>A</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A</sup>Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 80% to 100%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 60% to 80%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:10em;">Continuous IV infusion: Infants, Children, and Adolescents: <b>Note: </b>In general, administration of factor VIII 4 units/kg/hour will increase circulating factor VIII levels by 1 unit/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26674820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26674820'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Control and prevention of bleeding episodes: </i>Limited data available: <b>Note:</b> For patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22503305','lexi-content-ref-26674820','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22503305','lexi-content-ref-26674820','lexi-content-ref-32744769'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:14em;">Following initial bolus to achieve the desired factor VIII level: Initial dosing: 2 to 4 units/kg/hour; adjust dose based on frequent factor VIII assays and calculation of factor VIII clearance at steady-state using the following equations:</p>
<p style="text-indent:-2em;margin-left:14em;">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) / (plasma factor VIII level in units/<b>mL</b>)</p>
<p style="text-indent:-2em;margin-left:14em;">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired plasma factor VIII level in units/<b>mL</b>)</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Perioperative</i>
<i> management: </i>Limited data available: Initial: 25 to 50 units/kg prior to surgery, followed by continuous infusion at a rate of 3 to 5 units/kg/hour; regimen based on 2 studies evaluating use in pediatric surgery patients (age range: 0.9 to 17 years); rate was adjusted and additional boluses given as needed to maintain desired factor VIII level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530687','lexi-content-ref-12199670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530687','lexi-content-ref-12199670'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064833"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51064834"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F135731"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8825" href="/d/html/8825.html" rel="external">see "Factor VIII, human plasma-derived: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be400ab4-381a-4d5e-b65d-e32a52f7ab49">Hemophilia A, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing: </i>IV: </b>Utilize steps 1 to 3 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Determine desired factor VIII peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For patients without inhibitors and receiving emicizumab who experience breakthrough bleeding, antihemophilic factor should be dosed to target the desired peak factor VIII levels outlined in the table as emicizumab is not indicated for treatment of bleeding episodes.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor (Human) WFH Treatment Recommendations<sup>d</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Type of hemorrhage or surgery</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Lower-dose practice pattern</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Higher-dose practice pattern</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>May be longer if response is inadequate.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>Sometimes longer as secondary prophylaxis during physical therapy.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup>A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d</sup>WFH [Srivastava 2020].</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss: </b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial</b>:</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and Neck:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Gastrointestinal:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Calculate dose using desired peak factor VIII level from step 1 and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(desired peak factor VIII level − patient’s baseline factor VIII level) × body weight (kg)]/2</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note</b>: Factor VIII level units are units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Example for 50 kg patient with desired peak factor VIII level of 35 units/dL and baseline factor VIII level of 5 units/dL:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(35 units/dL − 5 units/dL) × 50 kg]/2 = 750 units of factor VIII</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Determine need for repeat dosing based on manufacturer’s recommended frequency of repeat dosing. <b>Note</b>: Frequency of administration must also take into consideration subsequent factor VIII activity measurements and the clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor (Human) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Bleeding event</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="center">
<p style="text-indent:0em;">Major severity</p></th>
<th align="center">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="center">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Hemofil-M</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose typically adequate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Koate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;margin-top:2em;">
<i>
<b>Continuous infusion dosing </b></i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk). To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV</b>: Administer an initial bolus to achieve the desired factor VIII level (see steps 1 and 2 under intermittent bolus dosing), then initiate continuous infusion at 2 to 4 units/kg/hour. Adjust dose based on frequent factor assays (at least daily) and calculation of factor VIII clearance at steady-state using the below equations.</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note</b>: With infusion dose increases, re-bolus should be considered to achieve target factor VIII level more quickly. See steps 1 and 2 under intermittent bolus dosing to determine re-bolus dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with moderate/severe hemophilia A, without inhibitors</b>:</i>
<b>IV: </b>25 to 40 units/kg of factor VIII concentrate every 2 to 3 days. Preferably, dosing should be tailored to ensure trough factor VIII levels of at least 1% and ideally ≥3% to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990965"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50988330"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block adr drugH1Div" id="F135707"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5%), nausea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased factor VIII inhibitors (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (≤5%), nervousness (10%), paresthesia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest tightness</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, chest pain, edema, flushing, hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, hypersensitivity reaction (including anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, fatigue, irritability, tonic-clonic seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ocular hyperemia, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, cough, cyanosis, dyspnea, hyperventilation</p></div>
<div class="block coi drugH1Div" id="F135720"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis) to antihemophilic factor (human) or any component of the formulation; hypersensitivity to mouse proteins (Hemofil M only).</p></div>
<div class="block war drugH1Div" id="F135704"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of factor VIII antibodies has been reported with antihemophilic factors; monitor for signs of formation of antibodies to factor VIII. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis) may occur; discontinue immediately if hypersensitivity symptoms occur and administer appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood types A, B, and AB: Contains trace amounts of blood groups A and B isohemagglutinins; use caution when large or frequently repeated doses are given to individuals with blood groups A, B, and AB. Monitor patients for signs of intravascular hemolysis and falling hematocrit; discontinue therapy and consider administration of serologically compatible type O red blood cells if progressive hemolytic anemia occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Products vary by preparation method; final formulations contain human albumin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Hepatitis A and B vaccination is recommended for all patients receiving plasma derivatives.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mouse protein: Hemofil M contains trace amounts of mouse protein; use is contraindicated in patients with hypersensitivity to mouse protein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• von Willebrand factor: Some products may contain naturally occurring von Willebrand factor for stabilization; however, efficacy has not been established for the treatment of von Willebrand disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Dosage requirements will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response. Frequency of use is determined by the severity of the disorder or bleeding pattern.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878330"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Formation of factor VIII inhibitors (neutralizing antibodies to AHF human) may occur; reported incidence is 3% to 52%; an increase of inhibitor antibody concentration is seen at 2 to 7 days, with peak concentrations at 1 to 3 weeks after therapy; children &lt;5 years of age are at greatest risk; higher doses of AHF may be needed if antibody is present; if antibody concentration is &gt;10 Bethesda units/mL, patients may not respond to larger doses and alternative treatment modalities may be needed; monitor patients appropriately. Allergic-type hypersensitivity reactions, including anaphylaxis, may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, dyspnea, faintness, or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed.</p></div>
<div class="block dosfc drugH1Div" id="F25573578"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F135714"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Koate: ~250 units (1 ea); ~500 units (1 ea); ~1000 units (1 ea) [contains albumin human, polyethylene glycol (macrogol), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemofil M: ~250 units (1 ea); ~500 units (1 ea); ~1000 units (1 ea); ~1700 units (1 ea) [contains albumin human, polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Koate-DVI: ~500 units (1 ea); ~1000 units (1 ea) [contains albumin human, polyethylene glycol (macrogol), polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F135700"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F21121603"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Hemofil M Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $1.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $1.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $1.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1700 unit (Price provided is per AHF Unit): $1.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Koate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $1.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $1.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $1.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Koate-DVI Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $1.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (per each): $1.58</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53565339"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">One unit of AHF is equal to the factor VIII activity present in 1 mL of normal human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of AHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large AHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL.</p></div>
<div class="block admp drugH1Div" id="F52612245"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV administration only; use administration sets/tubing provided by manufacturer (if provided). Administer through a separate line, do not mix with drugs or other IV fluids.</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV: Rate of administration should be determined by patient tolerability (maximum rates vary by product).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemofil M, Koate: 10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Monoclate-P: 2 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">WFH recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>): Infuse at a rate determined by age: Young children: 100 <b>units</b>/minute; Adults: 3 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous IV infusion: Further dilution after initial reconstitution is unnecessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530687','lexi-content-ref-26674820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530687','lexi-content-ref-26674820'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F135717"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer at a rate comfortable to the patient (≤10 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous infusion (off-label rate): Has also been administered as a continuous infusion to avoid peaks and troughs associated with intermittent infusions in patients who require prolonged treatment periods. Use a smart infusion pump with small volume infusion capability. Refer to protocols for product selection and preparation details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-32744769'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F135726"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store under refrigeration, 2°C to 8°C (36°F to 46°F); do not freeze. Use within 3 hours of reconstitution. Do not refrigerate after reconstitution, precipitation may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemofil M: May also be stored at room temperature not to exceed 30°C (86°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Koate: May also be stored at 25°C (77°F) for ≤6 months. Store in original package to protect from light.</p></div>
<div class="block usep drugH1Div" id="F53565469"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Control and prevention of bleeding episodes in patients with hemophilia A (classical hemophilia) and perioperative management of patients with hemophilia A (All indications: Monoclate-P, Hemofil M: FDA-approved in pediatric patients [age not specified] and adults; Koate: FDA approved in ages ≥2.5 years and adults). Has also been used to provide therapeutic effects in patients with acquired factor VIII inhibitors &lt;10 Bethesda units/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Antihemophilic Factor (Human) is not indicated for the treatment of von Willebrand disease.</p></div>
<div class="block mst drugH1Div" id="F11595784"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor VIII may be confused with Factor XIII</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Confusion may occur due to the omitting of  “Factor VIII” from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298757"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6217988"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F135722"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant carriers of hemophilia A may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor VIII levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor VIII concentrations increase in pregnant patients, factor VIII replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor VIII concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If a replacement product is indicated, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53565445"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor factor VIII levels prior to and during treatment; heart rate and blood pressure (before and during IV administration); monitor for signs and symptoms of bleeding, hemoglobin and hematocrit, and for hypersensitivity reactions; monitor for development of inhibitor antibodies by clinical observation (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda assay). In patients with blood groups A, B, or AB who receive large or frequent doses, monitor Hct, direct Coombs' test, and signs of intravascular hemolysis.</p></div>
<div class="block rerp drugH1Div" id="F53565331"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII (WFH [Srivastava 2013])</p>
<p style="text-indent:-2em;margin-left:4em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F135703"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Protein (factor VIII) in normal plasma which is necessary for clot formation and maintenance of hemostasis; activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot</p></div>
<div class="block phk drugH1Div" id="F135719"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Does not readily cross the placenta </p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean: 14.8 to 17.5 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F135723"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Factor viii | Koate dvi</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Emoclot | Fanhdi | Hemofil m | Koate dvi | Octanate | Optivate</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Haemoctin sdh | Octanate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Factane | Monoclate P</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Emoclot DI | Hemofil m | Koate | Octanate</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Fanhdi | Hemofil | Koate dvi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Haemoctin | Octanate</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Koate dvi | Octanate</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hemoraas | Kang si ping</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Emoclot | Factane | Fanhdi | Haemoctin sdh | Hemofil m | Koate | Koate dvi | Koate HP | Koate mr dvi | Octanate | Optivate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Beriate p | Criostat | Fanhdi | Haemoctin sdh | Octanate</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Beriate p | Fanhdi | Haemoctin sdh | Hemofil m | Monoclate P | Octanate | Optivate | Profilate</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Emoclot | Fanhdi | Octanate</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Hemofil m | Octanate | Octonativ-M</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Koate dvi | Octanate</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Fanhdi | Haemoctin | Hemofil m | Octanate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Amofil | Octafil | Octafil low</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Factane | Hemofil m | Monoclate | Octanate LV</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Fanhdi | Haemoctin | Hemofil m | Monoclate P | Octanate | Optivate | Profilate</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fanhdi | Haemoctin | Octanate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Haemoctin sdh | Koate | Koate dvi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Beriate hs | Beriate p | Fanhdi | Haemoctin sdh | Hemofil m | Koate dvi | Octanate | Octonativ-M</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aafact | Beriate | Haemoctin | Koate dvi | Koate HP | Koate HT | Octanate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Hemorel a</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Emoclot d.i. | Fanhdi | Haemoctin | Hemofil m | Koate | Octanate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Koate | Profilate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Monoclate P</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Beriate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Beriate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Haemoctin sdh | Hemofil m | Koate HP | Octanate</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Octanate</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cilveka koagulacijas faktora VIII | Haemoctin sdh | Hemofil m | Kaote dvi | Koate dvi | Octanate</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Beriate p | Fanhdi | Haemoctin sdh | Hemofil m | Koate dvi | Monoclate P | Octanate | Optivate | Plasmaclot</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Factor viii | Hemofil m | Octanate | Optivate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aafact | Octanate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Octanate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Factor viii | Octanate | Optivate</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hemofil m | Koate | Octanate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Emoclot | Fanhdi | Octanate</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hemofil m | Koate dvi | Koate HP</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Emoclot | Factor viii | Fanhdi | Hemofil m | Monoclate P | Octanate</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Factor viii green cross | Koate dvi</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fanhdi | Haemoctin sdh | Octanate | Optivate</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agemfil a | Beriate | Emoclot | Emoclot d.i. | Fanhdi | Haemoctin | Hemofil m | Koate dvi | Octanate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Factor viii | Koate dvi | Octanate | Optivate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ahf-Koncentrat | Beriate | Beriate p | Hemofil m | Koate | Monoclate P | Octanate | Octonativ-M | Profilate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Octanate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Octanate</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fanhdi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fanhdi | Haemoctin sdh | Hemofil m | Profilate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Emoclot DI | Haemoctin sdh | Octanate</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">AHF M | Beriate p | Emoclot | Factane | Factor viii | Fanhdi | Haemoctin sdh | Hemofil m | Koate dvi | Koate HP | Nordiate | Octanate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Beriate p | Factor viii | Haemoctin sdh | Koate dvi | Koate HP | Monoclate P</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Beriate | Emoclot | Koate dvi | Octanate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Emoclot | Haemoctin sdh | Hemofil m | Koate dvi | Koate HP</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Factor viii</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-5917942">
<a name="5917942"></a>Abildgaard CF, Simone JV, Corrigan JJ, et al. Treatment of Hemophilia With Glycine-Precipitated Factor VIII. <i>N Engl J Med</i>. 1966;275(9):471-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/5917942/pubmed" id="5917942" target="_blank">5917942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530687">
<a name="22530687"></a>Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/22530687/pubmed" id="22530687" target="_blank">22530687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010406">
<a name="12010406"></a>Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/12010406/pubmed" id="12010406" target="_blank">12010406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7974331">
<a name="7974331"></a>Berntorp E. Impact of Replacement Therapy on the Evolution of HIV Infection in Hemophiliacs. <i>Thromb Haemost</i>. 1994;71(6):678-683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/7974331/pubmed" id="7974331" target="_blank">7974331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12199670">
<a name="12199670"></a>Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. <i>Haemophilia</i>. 2002;8(5):629-634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/12199670/pubmed" id="12199670" target="_blank">12199670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HemofilM.1">
<a name="HemofilM.1"></a>Hemofil M (antihemophilic factor [human]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28873263">
<a name="28873263"></a>Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. <i>Haemophilia</i>. 2018;24(1):24-32. doi:10.1111/hae.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/28873263/pubmed" id="28873263" target="_blank">28873263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Koate.1">
<a name="Koate.1"></a>Koate (Antihemophilic Factor [Human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9351529">
<a name="9351529"></a>Liesner RJ. Prophylaxis in Haemophilic Children. <i>Blood Coagul Fibrinolysis</i>. 1997;8(suppl 1):S7-S10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/9351529/pubmed" id="9351529" target="_blank">9351529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7860443">
<a name="7860443"></a>Lusher JM. Transfusion Therapy in Congenital Coagulopathies. <i>Hematol Oncol Clin North Am</i>. 1994;8(6):1167-1180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/7860443/pubmed" id="7860443" target="_blank">7860443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7975511">
<a name="7975511"></a>Manucci PM. Impact of Recombinant Factor VIII on Hemophilia Care. <i>Vox Sang</i>. 1994;67(suppl 3):49-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/7975511/pubmed" id="7975511" target="_blank">7975511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1482660">
<a name="1482660"></a>Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. <i>Br J Haematol</i>. 1992;82(4):729-734. doi:10.1111/j.1365-2141.1992.tb06951.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/1482660/pubmed" id="1482660" target="_blank">1482660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHF.1">
<a name="NHF.1"></a>National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1640190">
<a name="1640190"></a>Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-Five Years' Experience of Prophylactic Treatment in Severe Haemophilia A and B. <i>J Intern Med</i>. 1992;232(1):25-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/1640190/pubmed" id="1640190" target="_blank">1640190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi:10.1111/1471-0528.14592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7942503">
<a name="7942503"></a>Peterson CW. Treating Hemophilia. <i>Am Pharm</i>. 1994;NS34(8):57-67. doi:10.1016/s0160-3450(15)30341-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/7942503/pubmed" id="7942503" target="_blank">7942503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503305">
<a name="22503305"></a>Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/22503305/pubmed" id="22503305" target="_blank">22503305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26674820">
<a name="26674820"></a>Prelog T, Dolničar MB, Kitanovski L. Low-dose continuous infusion of factor VIII in patients with haemophilia A. <i>Blood Transfus</i>. 2016;14(5):474-480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/26674820/pubmed" id="26674820" target="_blank">26674820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27214734">
<a name="27214734"></a>Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/27214734/pubmed" id="27214734" target="_blank">27214734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10444280">
<a name="10444280"></a>Scharrer I, Bray GL, Neutzling O. Incidence of Inhibitors in Haemophilia A Patients--A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII Concentrates. <i>Haemophilia</i>. 1999;5(3):145-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/10444280/pubmed" id="10444280" target="_blank">10444280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10938981">
<a name="10938981"></a>Shord SS, Lindley CM. Coagulation Products and Their Uses. <i>Am J Health Syst Pharm</i>. 2000;57(15):1403-1420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/10938981/pubmed" id="10938981" target="_blank">10938981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11307831">
<a name="11307831"></a>White GC, Rosendaal F, Aledort LM, et al. Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Thromb Haemost</i>. 2001;85(3):560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/11307831/pubmed" id="11307831" target="_blank">11307831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9873771">
<a name="9873771"></a>Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. <i>Haemophilia</i>. 1998;4(4):431-435.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-human-plasma-derived-pediatric-drug-information/abstract-text/9873771/pubmed" id="9873771" target="_blank">9873771</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12748 Version 203.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
